Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease

被引:85
作者
Popoli, Patrizia
Blum, David
Martire, Alberto
Ledent, Catherine
Ceruti, Stefania
Abbracchio, Maria P.
机构
[1] Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy
[2] INSERM, Jean Pierre Aubert Res Ctr, U815, IFR114, F-59045 Lille, France
[3] Univ Lille 2, Fac Med, Lille, France
[4] ULB, IRIBHN, Brussels, Belgium
[5] Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy
关键词
adenosine A(2A) receptors; Huntington's disease; neuroprotection; neurodegenerative mechanisms;
D O I
10.1016/j.pneurobio.2006.12.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The aim of this review is to summarize and critically discuss the complex role played by adenosine A(2A) receptors (A(2A)Rs) in Huntington's disease (HD)). Since A(2A)Rs are mainly localized on the neurons, which degenerate early in HD, and given their ability to stimulate glutamate outflow and inflammatory gliosis, it was hypothesized that they could be involved in the pathogenesis of HD, and that A(2A)R antagonists could be neuroprotective. This was further sustained by the demonstration that A(2A)Rs and underlying signaling systems undergo profound changes in cellular and animal models of HD. More recently, however, the equation A(2A) receptor blockade = neuroprotection has appeared too simplistic. First, it is now definitely clear that, besides mediating 'bad' responses (for example, stimulation of glutamate outflow and excessive glial activation), A(2A)Rs also promote 'good' responses (such as trophic and antinflammatory effects). This implies that A(2A)R blockade results either in pro-toxic or neuroprotective effects according to the mechanisms involved in a given experimental model. Second, since HD is a chronically progressive disease, the multiple mechanisms involving A(2A)Rs may play different relative roles along the degenerative process. Such different mechanisms can be influenced by A(2A)R activation or blockade in different ways, even leading to opposite outcomes depending on the time of agonist/antagonist administration. The number, and the complexity, of the possible scenarios is further increased by the influence of mutant Huntingtin on both the expression and functions of A(2A)Rs, and by the strikingly different effects mediated by A(2A)Rs expressed by different cell populations within the brain. (C) 2007 Published by Elsevier Ltd.
引用
收藏
页码:331 / 348
页数:18
相关论文
共 181 条
  • [61] 2-2
  • [62] Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage
    Fink, JS
    Kalda, A
    Ryu, H
    Stack, EC
    Schwarzschild, MA
    Chen, JF
    Ferrante, RJ
    [J]. JOURNAL OF NEUROCHEMISTRY, 2004, 88 (03) : 538 - 544
  • [63] Fredholm BB, 2001, PHARMACOL REV, V53, P527
  • [64] Fuxe K, 2001, ADV NEUROL, V86, P345
  • [65] FUXE K, 1974, MED BIOL, V52, P48
  • [66] Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules
    Gauthier, LR
    Charrin, BC
    Borrell-Pagès, M
    Dompierre, JP
    Rangone, H
    Cordelières, FP
    De Mey, J
    MacDonald, ME
    Lessmann, V
    Humbert, S
    Saudou, F
    [J]. CELL, 2004, 118 (01) : 127 - 138
  • [67] Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice.: Selective antagonism of adenosine A2A receptors reduces transmitter outflow
    Gianfriddo, M
    Melani, A
    Turchi, D
    Giovannini, MG
    Pedata, F
    [J]. NEUROBIOLOGY OF DISEASE, 2004, 17 (01) : 77 - 88
  • [68] GOA Y, 1994, LIFE SCI, V55, pPL61
  • [69] A COMPARISON OF NEUROLOGICAL, METABOLIC, STRUCTURAL, AND GENETIC EVALUATIONS IN PERSONS AT RISK FOR HUNTINGTONS-DISEASE
    GRAFTON, ST
    MAZZIOTTA, JC
    PAHL, JJ
    STGEORGEHYSLOP, P
    HAINES, JL
    GUSELLA, J
    HOFFMAN, JM
    BAXTER, LR
    PHELPS, ME
    [J]. ANNALS OF NEUROLOGY, 1990, 28 (05) : 614 - 621
  • [70] Bioenergetics and glutamate excitotoxicity
    Greene, JG
    Greenamyre, JT
    [J]. PROGRESS IN NEUROBIOLOGY, 1996, 48 (06) : 613 - +